Loading stock data…
HURA
$2.04-0.01 (-0.24%)
Market OpenUpdated 3:41 PM EDT
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TuHURA Biosciences, Inc. in the Healthcare sector is trading at $2.04 with a market capitalization of $135M. Wall Street consensus targets $8.04 (5 analysts), implying a +294.1% move over the next 12 months. The stock is currently 48% below its 52-week high of $3.90, remaining 7.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +294.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.04
Potential Downside
0%
Whystock Fair Value$2.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome prim...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$135.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-133.35%
Volume
Today's trading volume
329,022
Recent News
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?
TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the 10 Unstoppable Stocks That Could Double Your Money. TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive […]
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit
TuHURA Biosciences, Inc. ( NASDAQ:HURA ) is possibly approaching a major achievement in its business, so we would like...
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake
NasdaqCM:HURA 1 Year Share Price vs Fair Value Explore TuHURA Biosciences's Fair Values from the Community and select...